In a landmark phase 3 clinical trial, the international team, coordinated by Dr Patrick Yu-Wai-Man from the University of Cambridge and Dr Jos-Alain Sahel from the University of Pittsburgh and Institut de la Vision, Paris, successfully treated 37 patients suffering from Leber hereditary optic neuropathy (LHON). Subject to further trials, the treatment could help thousands of people across the world to regain and retain some of their sight.
The study, published today in the journal Science Translational Medicine, indicates that 78% of treated patients experienced significant visual improvement in both eyes. It suggests that the improvement in vision in untreated eyes could be due to the transfer of viral vector DNA from the injected eye.
LHON affects a specific type of retinal cells, known as retinal ganglion cells, causing optic nerve degeneration and rapidly worsening vision in both eyes. Within a few weeks of disease onset, the vision of most people affected deteriorates to levels at which they are considered legally blind. Visual recovery occurs in less than 20% of cases and few achieve vision better than 20/200 (largest letter on a standard eye chart). LHON affects approximately 1 in 30,000 people, mostly men, with symptoms usually emerging in their 20s and 30s. The majority of patients carry the m.11778G>A mutation in the MT-ND4 gene. Existing treatment for this blinding optic neuropathy remains limited.
As someone who treats these young patients, I get very frustrated about the lack of effective therapies, said senior investigator Dr Sahel, a professor of ophthalmology at the University of Pittsburgh. These patients rapidly lose vision in the course of a few weeks to a couple of months. Our study provides a big hope for treating this blinding disease in young adults.
The researchers injected rAAV2/2-ND4 a viral vector containing modified cDNA into the vitreous cavity at the back of one eye of 37 patients who had suffered vision loss for between 6 to 12 months. Their other eye received a sham injection. The technology, called mitochondrial targeting, was developed by the Institut de la Vision in Paris, France, and licensed to GenSight Biologics.
International coordinating investigator and neuro-ophthalmologist Dr Yu-Wai-Man, from Cambridges Department of Clinical Neurosciences and Moorfields Eye Hospital, London, said: We expected vision to improve in the eyes treated with the gene therapy vector only. Rather unexpectedly, both eyes improved for 78% of patients in the trial following the same trajectory over 2 years of follow-up.
Treated eyes showed a mean improvement in best-corrected visual acuity (BCVA) of 15 letters on an ETDRS chart, representing three lines of vision, while a mean improvement of 13 letters was observed in the sham-treated eyes. As some patients were still in the dynamic phase of the disease process upon enrolment, the visual gain from the nadir (worst BCVA for each eye) was even larger, reaching 28.5 letters for the treated eyes and 24.5 letters for sham-treated eyes.
Dr Yu-Wai-Man said: By replacing the defective MT-ND4 gene, this treatment rescues the retinal ganglion cells from the destructive effects of the m.11778G>A mutation, preserving function and improving the patients visual prognosis. The outcomes can be life-changing.
The researchers found that treated eyes were around three times more likely to achieve vision better than or equal to 20/200. Patient-reported outcome measures evaluated using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) also confirmed the positive impact of treatment on quality of life and psychosocial well-being.
The researchers then conducted a study in cynomolgus macaques to investigate how the treatment of one eye could bring about improvement in the other. Macaques have a visual system similar to that of humans, which allows the distribution and effects of the gene therapy vector to be studied in much greater detail. Unilateral injection of rAAV2/2-ND4 was administered and after three months, tissues from various parts of the eye and the brain were analyzed to detect and quantify the presence of viral vector DNA using a transgene-specific quantitative PCR assay.
Viral vector DNA was detected in the anterior segment, retina and optic nerve of the untreated eye. The unexpected visual improvement observed in the untreated eyes could therefore reflect the interocular diffusion of rAAV2/2-ND4. Further investigations are needed to confirm these findings and whether other mechanisms are contributing to this bilateral improvement.
Dr Yu-Wai-Man said: Saving sight with gene therapy is now a reality. The treatment has been shown to be safe and we are currently exploring the optimal therapeutic window.
Our approach isnt just limited to vision restoration, added Dr Sahel. Other mitochondrial diseases could be treated using the same technology.
Reference: Yu-Wai-Man P, Newman NJ, Carelli V, et al.Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy.Sci. Transl. Med. 2020;12(573). doi:10.1126/scitranslmed.aaz7423
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.
Here is the original post:
- A look at prospects for the US gene therapy industry - BioPharma-Reporter.com - December 27th, 2021
- Taysha Gene Therapies Added to the ICE Biotechnology Index - BioSpace - December 27th, 2021
- Technology Developments in Viral Vector Manufacturing for Cell and Gene Therapies - Yahoo Finance - December 27th, 2021
- Triangle gene editing firms CEO: There is a revolution occurring in medicine - WRAL TechWire - December 27th, 2021
- Global Regenerative Medicine Market is Expected to Reach USD 57.08 Billion by 2027, Growing at a CAGR of 11.27% Over the Forecast Period. -... - December 27th, 2021
- 2021 Research Highlights Human Health Advances - National Institutes of Health - December 27th, 2021
- Long reads: The USA TODAY stories readers spent the most time with in 2021 - USA TODAY - December 27th, 2021
- Which philosophy helps us confront the crises that beset us... we first or me first? - The Guardian - December 27th, 2021
- Vaccines are just the beginning for RNA. The technology is being tested on heart and liver diseases. - The Philadelphia Inquirer - December 27th, 2021
- Gene Therapy Successes - University of Utah - December 14th, 2021
- Gene Therapy Pros and Cons - Biolyse - December 14th, 2021
- Syrian refugee is thriving five years after last-gasp gene therapy - STAT - STAT - December 14th, 2021
- New Technology is One Step Closer to Targeted Gene Therapy - Caltech - December 14th, 2021
- N4 Pharma to Focus Resources on Advancing Gene Therapy Work - MarketWatch - December 14th, 2021
- CF Foundation Funding Bolsters Gene Therapy Research - Cystic Fibrosis News Today - December 14th, 2021
- BMS and Kite Unveil CAR-T Successes in Lymphoma - BioSpace - December 14th, 2021
- Capsida Biotherapeutics Poised to Capitalize on Industry-leading Gene Therapy Technology With New CEO, CSO, and CTO - PRNewswire - December 14th, 2021
- URMC & RIT faculty awarded patent for gene transfer technology that could transform cancer therapies - URMC - December 14th, 2021
- Global Gene Editing Market Research Report 2021 Featuring CRISPR, GenScript, Horizon Discovery Group, Integrated DNA Technologies and New England... - December 14th, 2021
- Bridging the cell and gene therapy gap - The Scotsman - December 14th, 2021
- GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ Injections at 2-Year Follow-Up of REFLECT Phase III Trial - Business... - December 14th, 2021
- At FDA meeting, gene therapy experts wrestle with field's blindspots - BioPharma Dive - September 5th, 2021
- Astellas again hits pause on gene therapy trial - BioPharma Dive - September 5th, 2021
- Joe Rogan falsely says mRNA vaccines are 'gene therapy' - PolitiFact - September 5th, 2021
- Connecticuts Children first to enroll affordable gene therapy - WTNH.com - September 5th, 2021
- Cell And Gene Therapy Manufacturing Market Size Worth $57.4 Billion By 2028: Grand View Research, Inc. - PRNewswire - September 5th, 2021
- Global Gene Therapy Market Top Companies, Size, Growth Analysis, Segmentation, Industry Outlook Analysis , and Forecast 2020 to 2027 UNLV The Rebel... - September 5th, 2021
- Regenerative medicine 2021: report highlights record year for the sector - Clinical Trials Arena - September 5th, 2021
- Science Will Win Podcast: Season 1 - Pfizer - September 5th, 2021
- GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ -... - September 5th, 2021
- Novartis, Gates Foundation pursue a simpler gene therapy for sickle cell - STAT - February 17th, 2021
- Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and... - February 17th, 2021
- Avance Biosciences Expanding Houston Campus in Support of Cell and Gene Therapy Drug Development - BioSpace - February 17th, 2021
- Sensorion and Institut Pasteur announce new gene therapy collaboration - BioPharma-Reporter.com - February 17th, 2021
- Gene Therapy GS010 Safe, Well-Tolerated for LHON Patients - MD Magazine - February 17th, 2021
- bluebird bio 'baffled' after NICE rejects beta-thalassaemia gene therapy - - pharmaphorum - February 17th, 2021
- Global Gene Therapy Market Outlook to 2030 - by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of... - February 17th, 2021
- GenSight Biologics' gene therapy proves safe in LHON trial - Clinical Trials Arena - February 17th, 2021
- Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference - GlobeNewswire - February 17th, 2021
- Beti-Cel Gene Therapy Frees Patients With Beta-Thalassemia From Red Blood Cell Transfusions - OncLive - February 17th, 2021
- Forge Biologics Receives FDA Fast Track, Orphan Drug, and Rare Pediatric Disease Designations for FBX-101 Gene Therapy for Patients with Krabbe... - February 17th, 2021
- CDMO Vigene plots cell and gene therapy manufacturing expansion, adding 245 new jobs along the way - FiercePharma - February 17th, 2021
- Taysha Gene Therapies Announces Formation of Independent Scientific Advisory Board - Business Wire - February 17th, 2021
- bluebird bio's beta-thalassaemia gene therapy rejected by NICE - PharmaTimes - February 17th, 2021
- Europe Cell and Gene Therapy Market Industry Outlook and Forecast Report 2021-2026 with Data-driven Insights on the Impact of COVID-19 -... - February 17th, 2021
- Europe Cell and Gene Therapy Market Report 2021-2026: Prominent Players are Novartis, Spark Therapeutics, Amgen, Gilead Sciences & Organogenesis -... - February 17th, 2021
- Rentschler Biopharma to build new cell and gene therapy capabilities in the UK - BioSpace - February 17th, 2021
- Gene Therapy Market to Reflect Impressive Growth Rate During 2020-2027 AveXis, Vineti, uniQure NV, Spark Therapeutics KSU | The Sentinel Newspaper -... - February 17th, 2021
- Genethon and WhiteLab Genomics Join Forces to Enhance Gene Therapy Through Artificial Intelligence - BioSpace - February 17th, 2021
- Avrobio Gene Therapy Shows Early Promise in Fabry, Other Rare Lysosomal Diseases - BioSpace - February 11th, 2021
- Global Genes Announces New Multimedia Series Focused on Advances in Gene Therapy and Editing, in Collaboration with the National Institutes of Health... - February 11th, 2021
- The Europe cell and gene therapy market by revenue is expected to grow at a CAGR of over 23% during the period 20212026 - GlobeNewswire - February 11th, 2021
- FLT201 Shows Promise as a Gene Therapy for Gaucher Disease - MD Magazine - February 11th, 2021
- NICE Draft Guidance Recommends that Patients be Denied Access to bluebird bio's Gene Therapy for Life-Limiting Rare Blood Diseas - PharmiWeb.com - February 11th, 2021
- Dyno Therapeutics Announces Publication in Nature Biotechnology Demonstrating Use of Artificial Intelligence to Generate Unprecedented Diversity of... - February 11th, 2021
- Breakthrough gene therapy helps Utah boy thrive - Yahoo News - February 11th, 2021
- Taysha Gene Therapies Announces Participation in Upcoming Investor Healthcare Conferences - Yahoo Finance - February 11th, 2021
- Global Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market to 2030 - Insight, Epidemiology and Forecasts - ResearchAndMarkets.com - Yahoo... - February 11th, 2021
- Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium 2021 - GlobeNewswire - February 11th, 2021
- Paragon Biosciences Expands Cell And Gene Therapy Platform - Contract Pharma - February 11th, 2021
- FDA Clears IND Application for Passage Bio's Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare... - February 11th, 2021
- Gene Therapy Market by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of Administration, and Key... - February 11th, 2021
- FDA approves third gene therapy for large B-cell lymphoma - European Pharmaceutical Review - February 11th, 2021
- Europe Cell and Gene Therapy Market Size to Reach Revenues of USD 2.9 Billion by 2026 - Arizton - PRNewswire - February 7th, 2021
- FDA Issues More Guidance on Gene and Cell Therapy Products - JD Supra - February 7th, 2021
- Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease - BioSpace - February 7th, 2021
- The gene therapy market is projected to be worth USD 14.6 billion in 2030, growing at a CAGR of 30%, over the next decade, claims Roots Analysis -... - February 7th, 2021
- AGTC Executives Awarded First Place in the BioProcess International Reader's Choice Awards, Cell & Gene Therapies Category - GlobeNewswire - February 7th, 2021
- Retinal Gene Therapy Market: Advent of High-end Technologies to Support Development of the Market - BioSpace - February 7th, 2021
- Sio Gene Therapies Announces Receipt of $11.6 Million from Closing of the Sale of Arvelle Therapeutics - BioSpace - February 7th, 2021
- Welsh, Carson, Anderson & Stowe Commits $250 Million in a Strategic Partnership with Kiniciti, a Newly-Formed Platform Investing in Cell and Gene... - February 7th, 2021
- Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis)... - February 7th, 2021
- Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium -... - February 7th, 2021
- Decibel and Catalent Sign Development and Manufacturing Agreement for Dual-Vector Gene Therapy for the Treatment of Congenital Hearing Loss - Yahoo... - February 7th, 2021
- Meeting the commercialization challenge of a surging gene and cell therapy market - FierceBiotech - February 7th, 2021
- Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult - PharmiWeb.com - February 7th, 2021
- Adverum Biotechnologies Announces Publication of Preclinical Long-Term Safety Data on ADVM-022 IVT Gene Therapy - BioSpace - February 7th, 2021
- Avacta JV raises $7.3m for cell and gene therapy push | Business Weekly - Business Weekly - February 7th, 2021
- Taysha Gene Therapies Highlights Strategic Priorities and Provides 2021 Business Outlook - Business Wire - February 7th, 2021
- FDA's New Guidance on Cell and Gene Therapy Recommends Assessment of COVID-19 Transmission Risks - Lexology - February 7th, 2021